CRP and hyperlipidemia: JUPITER included nearly 18,000 subjects, which was designed to test the hypothesis that treatment with rosuvastatin for primary prevention would reduce vascular events in relatively healthy people with high-sensitivity C-reactive protein (CRP) but without hyperlipidemia [20].